Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 15/20 | 0.59 |
| ▸ | JAK2 | O60674 | 2/20 | 0.52 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL488676 | 0.92 | MET (0.55) | METJAK2MAP4K3ALK | |
| SCHEMBL1823431 | 0.88 | MET (0.57) | METJAK2MAP4K3ALK | |
| SCHEMBL488538 | 0.85 | MET (0.54) | MET | |
| SCHEMBL488799 | 0.82 | MET (0.64) | MET | |
| SCHEMBL15778791 | 0.82 | MET (0.53) | METJAK2MAP4K3ALK | |
| SCHEMBL17224826 | 0.81 | MET (0.45) | METJAK2MAP4K3 | |
| SCHEMBL10215090 | 0.80 | JAK2 (0.58) | METJAK2MAP4K3ALK | |
| SCHEMBL488763 | 0.80 | MET (0.44) | MET | |
| SCHEMBL26916900 | 0.78 | MET (0.48) | METJAK2MAP4K3 | |
| SCHEMBL29857597 | 0.78 | MET (0.48) | METJAK2MAP4K3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160206608-A1 | CRIZOTINIB FOR USE IN THE TREATMENT OF CANCER | PFIZER INC. (US) | 2016-07-21 | — | — | US | disclosed |
| US-8952002-B2 | Aminoheteroaryl compounds and preparation method and use thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2015-02-10 | — | — | US | disclosed |
| US-20140357613-A1 | Aminoheteroaryl compounds and preparation method and use thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2014-12-04 | — | — | US | disclosed |
| EP-2805946-A1 | AMINO HETEROARYL COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Allist Pharmaceuticals, Inc. (CN) | 2014-11-26 | — | — | EP | disclosed |
| CN-104144923-A | Amino heteroaryl compound and preparation method and application thereof | ALLIST PHARMACEUTICALS INC | 2014-11-12 | — | — | CN | disclosed |
| US-20140288086-A1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2014-09-25 | — | — | US | disclosed |
| EP-2764866-A1 | Inhibitors of nedd8-activating enzyme | IP Gesellschaft für Management mbH (DE) | 2014-08-13 | — | — | EP | disclosed |
| US-8785632-B2 | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2739284-A1 | CRIZOTINIB FOR USE IN THE TREATMENT OF CANCER | Pfizer Inc (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-1603570-B9 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20060178374-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| US-20060128724-A1 | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
| US-20060046991-A1 | Crizotinib, a c-Met protein kinase inhibitor anticancer agent; 3-[(R)-1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine is crizotinib | AGOURON PHARMACEUTICALS, INC. | 2006-03-02 | — | — | US | disclosed |
| WO-2006021884-A2 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021881-A2 | PYRAZOLE-SUBSTITUTED AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021886-A1 | AMINOHETEROARYL COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | PFIZER INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| EP-1603570-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
| WO-2004076412-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160206608-A1 | CRIZOTINIB FOR USE IN THE TREATMENT OF CANCER | ROS1, ALK, ABL1 | MET 6/4885JAK2 75/4885MAP4K3 311/4885 |
| US-20060128724-A1 | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP3K15, MAP3K19 | MET 1/4885JAK2 249/4885MAP4K3 10/4885 |
| US-20060046991-A1 | Crizotinib, a c-Met protein kinase inhibitor anticancer agent; 3-[(R)-1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine is crizotinib | ALK, MET, ERBB2 | MET 2/4885JAK2 192/4885MAP4K3 78/4885 |
| US-20140357613-A1 | Aminoheteroaryl compounds and preparation method and use thereof | MET, HGF, HDGF | MET 1/4885JAK2 80/4885MAP4K3 704/4885 |
| US-20060178374-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP3K15, CDC42BPA | MET 1/4885JAK2 342/4885MAP4K3 14/4885 |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | MET, ERBB2, CDK4 | MET 1/4885JAK2 8/4885MAP4K3 56/4885 |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP4K1, MAP4K2 | MET 1/4885JAK2 287/4885MAP4K3 8/4885 |
| US-20140288086-A1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | MET, MAP3K15, MAP3K1 | MET 1/4885JAK2 350/4885MAP4K3 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.